About this trial
The rupture or erosion of an atherosclerotic plaque with thrombosis or embolization often underlie heart attacks and strokes. The early identification of patients with atherosclerotic plaques prone to rupture or erosions, vulnerable plaques (VP), and their treatment before the occurrence of events is, therefore, one of the greatest cardiovascular challenges today. Possible approaches for early detection of VP include imaging techniques allowing visualization of plaque structure, circulating biomarkers and better understanding of the pathophysiologic mechanisms of the disease. In the carotid plaque imaging project the investigators study human atherosclerotic plaques (that are removed by endarterectomy) to disclose their underlying structure and mechanisms, finding possible novel therapeutic targets or markers for VP. The investigators also study plaque structure with imaging methods and try to develop new ways to detect VP using circulating or imaging markers.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients older than 18 years old, male or female that are eligible for carotid endarterectomy due to atherosclerosis and that can provide informed consent.
Disqualifiers
Patients younger than 18 years old that cannot provide informed consent; pregnant.
Trial population
All patients with carotid stenosis undergoing endarterectomy at Skåne University Hospital (SUS), Malmö, Sweden.
Trial design
Cohort
Prospective
Treatments tested in this trial
Observational study
Other intervention
Treatment groups
Trial outcomes
Primary outcomes
Number of participants suffering post-operative cardiovascular events (by 2025)
Post-operative myocardial infarction, stroke, transient ischaemic attack, amaurosis fugax, cardiovascular death (according to Swedish National Registers)
Number of participants suffering post-operative cardiovascular events (by 2027)
Post-operative myocardial infarction, stroke, transient ischaemic attack, amaurosis fugax, cardiovascular death (according to Swedish National Registers)
Number of participants suffering post-operative cardiovascular events (by 2029)
Post-operative myocardial infarction, stroke, transient ischaemic attack, amaurosis fugax, cardiovascular death (according to Swedish National Registers)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Lund University
Lead sponsor
Region Skane
Collaborator
The Swedish Research Council
Collaborator
Swedish Heart Lung Foundation
Collaborator
Skåne University Hospital funds (incl. the Medical Training and Research Agreement/ALF)
Collaborator
Swedish Foundation for Strategic Research
Collaborator